The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1 | N | Nervous system | |
2 | N02 | Analgesics | |
3 | N02C | Antimigraine preparations | |
4 | N02CC | Selective serotonin (5HT1) agonists |
Code | Title | |
---|---|---|
N02CC01 | Sumatriptan | |
N02CC02 | Naratriptan | |
N02CC03 | Zolmitriptan | |
N02CC04 | Rizatriptan | |
N02CC05 | Almotriptan | |
N02CC06 | Eletriptan | |
N02CC07 | Frovatriptan | |
N02CC08 | ||
N02CC51 |
Active Ingredient | Description | |
---|---|---|
Almotriptan |
Almotriptan is a selective 5-HT1B and 5-HT1D receptor agonist. These receptors mediate vasoconstriction of certain cranial vessels, as demonstrated in studies using isolated human tissue preparations. |
|
Eletriptan |
Eletriptan is a selective agonist at the vascular 5-HT1B and neuronal 5-HT1D receptors. Eletriptan also exhibits high affinity for the 5-HT1F receptor which may contribute to its anti-migraine mechanism of action. |
|
Frovatriptan |
Frovatriptan is a selective agonist for 5-HT receptors. Frovatriptan is believed to act selectively on extracerebral, intracranial arteries to inhibit the excessive dilatation of these vessels in migraine. |
|
Naratriptan |
Naratriptan has been shown to be a selective agonist for 5 hydroxytryptamine1 (5-HT1) receptors mediating vascular contraction. This receptor is found predominantly in intracranial (cerebral and dural) blood vessels. Naratriptan is indicated for the acute treatment of migraine attacks with or without aura. |
|
Rizatriptan |
Rizatriptan binds selectively with high affinity to human 5-HT1B and 5-HT1D receptors. The therapeutic activity of rizatriptan in treating migraine headache may be attributed to its agonist effects at 5-HT1B and 5-HT1D receptors on the extracerebral intracranial blood vessels that are thought to become dilated during an attack and on the trigeminal sensory nerves that innervate them. |
|
Sumatriptan |
Sumatriptan has been demonstrated to be a specific and selective 5-Hydroxytryptamine1 (5HT1D) receptor agonist with no effect on other 5HT receptor (5-HT2 - 5-HT7) subtypes. The vascular 5-HT1D receptor is found predominantly in cranial blood vessels and mediates vasoconstriction. |
|
Zolmitriptan |
Zolmitriptan has been demonstrated to be a selective agonist for the vascular human recombinant 5HT1B and 5HT1D receptor subtypes. Zolmitriptan is a high affinity 5HT1B/1D receptor agonist with modest affinity for 5HT1A receptors. |
Title | Information Source | Document Type | |
---|---|---|---|
ALMOGRAN Film-coated tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
AMERGE Film-coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
FROVA Tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
IMIGRAN Nasal spray, solution | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
IMIGRAN Solution for injection | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
IMIGRAN Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
IMITREX Film-coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
IMITREX Nasal spray | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
IMITREX Solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
MAXALT Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
MIGARD Film-coated tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
NARAMIG Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
RELPAX Film-coated tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
REYVOW Tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
SUMATRAN Tablet | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
ZOMIG Film-coated tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
ZOMIG Nasal spray | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |